Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2026
Task-guided accelerated cTBS simultaneously treats depression and social dysfunction in patients with major depressive disorder: a randomized clinical trial.
Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dose effect of bilateral transcranial magnetic stimulation for depression and anxiety in a real-world clinical setting.Journal of mood and anxiety disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Current antidepressant therapies predominately target symptom remission in major depressive disorder (MDD) but often overlook social dysfunction, which is a critical determinant of functional recovery. Individualized, accelerated continuous theta burst stimulation (cTBS) targeting the right dorsolateral prefrontal cortex (R.DLPFC) may offer a potential therapeutic approach for concurrently improving clinical and psychosocial outcomes in MDD. In this randomized, double-blind, sham-controlled trial, 70 patients with MDD were randomly assigned to receive either active (n = 37) or sham (n = 33) accelerated cTBS for 2 weeks. The treatments targeted individualized R.DLPFC sites, which were identified by task-evoked brain activation during a social interactive task (Ultimatum Game, UG). Depressive and anxiety symptoms, general social functioning, UG-derived behavioral and computational modeling indices (e.g., learning rates), and effective connectivity in social processing networks were assessed pre- and post-treatment. Active accelerated cTBS significantly outperformed sham stimulation in reducing depressive and anxiety symptoms and improving general social functioning (all ps < 0.001). The active group also demonstrated enhanced cooperation behavior (p = 0.002) and increased learning rates (89% HDI: [0.01, 0.21]). And the active group exhibited increased effective connectivity from the right insula to the R.DLPFC and stable effective connectivity from the anterior cingulate cortex (ACC) to the left insula after treatment, which was different from the sham group (Pp > 0.95). No severe adverse events occurred. Individualized, accelerated cTBS targeting task-evoked activation in the R.DLPFC safely and effectively improves clinical symptoms and social dysfunction in MDD. Altered effective connectivity among the DLPFC, insula and ACC may provide mechanistic insights into its therapeutic effects. Trial Registration: chictr.org.cn; ChiCTR2300068273.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.